[go: up one dir, main page]

NZ596015A - Method and composition for the treatment of pain and/or inflammation - Google Patents

Method and composition for the treatment of pain and/or inflammation

Info

Publication number
NZ596015A
NZ596015A NZ596015A NZ59601511A NZ596015A NZ 596015 A NZ596015 A NZ 596015A NZ 596015 A NZ596015 A NZ 596015A NZ 59601511 A NZ59601511 A NZ 59601511A NZ 596015 A NZ596015 A NZ 596015A
Authority
NZ
New Zealand
Prior art keywords
pain
inflammation
treatment
composition
vitamin
Prior art date
Application number
NZ596015A
Inventor
John Lyftogt
Michael Cushman
Original Assignee
Anzamed Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anzamed Internat Ltd filed Critical Anzamed Internat Ltd
Priority to NZ596015A priority Critical patent/NZ596015A/en
Priority to PCT/NZ2012/000195 priority patent/WO2013062424A1/en
Publication of NZ596015A publication Critical patent/NZ596015A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

596015 The disclosure relates to a method and composition for the treatment of pain and/or inflammation, especially neuropathic pain and neurogenic inflammation. A topical or transdermal composition containing vitamin D, one or more saccharides or sugar alcohols and/ or a salt or salts is disclosed which surprisingly act synergistically to relieve pain. In some embodiments, the vitamin D may comprise vitamin D3, for example cholecalciferol.
NZ596015A 2011-10-26 2011-10-26 Method and composition for the treatment of pain and/or inflammation NZ596015A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ596015A NZ596015A (en) 2011-10-26 2011-10-26 Method and composition for the treatment of pain and/or inflammation
PCT/NZ2012/000195 WO2013062424A1 (en) 2011-10-26 2012-10-25 Method and composition for the treatment of pain and/or inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ596015A NZ596015A (en) 2011-10-26 2011-10-26 Method and composition for the treatment of pain and/or inflammation

Publications (1)

Publication Number Publication Date
NZ596015A true NZ596015A (en) 2014-04-30

Family

ID=48168134

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596015A NZ596015A (en) 2011-10-26 2011-10-26 Method and composition for the treatment of pain and/or inflammation

Country Status (2)

Country Link
NZ (1) NZ596015A (en)
WO (1) WO2013062424A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150283163A1 (en) * 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
IN2014CH01872A (en) 2014-04-09 2015-05-08 Nanoceutica Lab Pvt Ltd
AU2016102480A4 (en) * 2015-05-12 2021-12-23 Brinnson IP Limited New treatment methods utilising lactose compositions
CN104997806A (en) * 2015-07-23 2015-10-28 四川科伦药业股份有限公司 Compound sodium acetate ringer injection and preparation method and quality control method thereof
CA3164386A1 (en) 2020-02-18 2021-08-26 Kana Hashimoto Oral care composition
CN113440440B (en) * 2021-07-26 2022-06-07 宝萃生物科技有限公司 Skin barrier repair composition and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298971B6 (en) * 1998-03-04 2008-03-26 Teijin Limited Lotions based on Active vitamin D3 emulsions
EP1455778A4 (en) * 2001-12-19 2007-09-12 The Quigley Corp METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
US20060275237A1 (en) * 2005-05-09 2006-12-07 Bissett Donald L Skin care compositions containing idebenone

Also Published As

Publication number Publication date
WO2013062424A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
WO2011007183A3 (en) Skin care composition for the treatment of acne vulgaris
NZ596015A (en) Method and composition for the treatment of pain and/or inflammation
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
MX359626B (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction.
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
WO2009129531A3 (en) Bupivacaine formulation in a polyorthoester carrier
MX2014008021A (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain.
MX363465B (en) Treatment of submental fat.
WO2012050831A3 (en) Combination treatment for dermatological conditions
HK1201486A1 (en) Composition containing an extract of a sequential or simultaneous fermentation
WO2009129527A3 (en) Baclofen formulation in a polyorthoester carrier
MX2017015012A (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
EA201401031A1 (en) A HALF-LEVELED COMPOSITION FOR LOCAL APPLICATION THAT CONTAINS Pyrphenidone and Modified Diallyldisulfide Oxide (M-DDO) to Remove or Prevent Ugrey
MX2015015200A (en) "inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof".
GB2525517A (en) Topical preparation for pain relief
WO2011085013A3 (en) Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
WO2011001111A3 (en) Use of jasmonic acid to treat oily skin
WO2012053014A3 (en) Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene
BR112015006063A2 (en) heteroaromatic compounds, process for preparing compounds, pharmaceutical compositions, uses and method of treatment for acute and chronic pain
PH12013502563A1 (en) Dha and epa in the reduction of oxidative stress

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: PHARMACEUTICAL COMPOUNDING NZ LIMITED, NZ

Free format text: OLD OWNER(S): PHARMACEUTICAL COMPOUNDING NZ LIMITED; PHARMACEUTICAL COMPOUNDING NZ LIMITED; JOHN LYFTOGT; MICHAEL CUSHMAN

Owner name: MICHAEL CUSHMAN, NZ

Free format text: OLD OWNER(S): PHARMACEUTICAL COMPOUNDING NZ LIMITED; PHARMACEUTICAL COMPOUNDING NZ LIMITED; JOHN LYFTOGT; MICHAEL CUSHMAN

ASS Change of ownership

Owner name: PHARMACEUTICAL COMPOUNDING NZ LIMITED, NZ

Free format text: OLD OWNER(S): PHARMACEUTICAL COMPOUNDING NZ LIMITED; MICHAEL CUSHMAN

ASS Change of ownership

Owner name: ANZAMED INTERNATIONAL LIMITED, NZ

Free format text: OLD OWNER(S): PHARMACEUTICAL COMPOUNDING NZ LIMITED

PSEA Patent sealed
ASS Change of ownership

Owner name: JAN ANNE LYFTOGT, NZ

Effective date: 20160519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2017 BY CREATEIP

Effective date: 20160815

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2018 BY CREATEIP

Effective date: 20170801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2019 BY CREATEIP

Effective date: 20180727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2020 BY CREATEIP

Effective date: 20190801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2021 BY CREATEIP

Effective date: 20200728

ASS Change of ownership

Owner name: HOROPITO LIMITED, GB

Effective date: 20201214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2022 BY CREATEIP

Effective date: 20210823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2023 BY CREATEIP

Effective date: 20220928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2024 BY CREATEIP

Effective date: 20231019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2025 BY CREATEIP

Effective date: 20241017